House committee grills Emergent CEO Bob Kramer over J&J vaccine debacle, ill-timed stock sale
With Maryland CDMO Emergent BioSolutions still holding formation as the FDA mulls over operations at its Bayview Baltimore plant, CEO Bob Kramer has been hammered for sending mixed messages on the screwup that led to the inspection in the first place. House leaders had some questions for him about that Wednesday — and it wasn’t pretty.
In a contentious hearing Wednesday afternoon, members of the House Subcommittee on the Coronavirus Crisis grilled Kramer over the state of the Bayview plant and the poor optics behind his sale of company stock just weeks before news broke that Emergent had trashed a batch of Johnson & Johnson’s Covid-19 vaccine after an ingredients screwup.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.